Knight Therapeutics Inc. announced that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.98 CAD | +0.67% | +1.01% | +15.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.22% | 440M | |
+7.22% | 72.81B | |
+12.72% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
+20.34% | 2.42B | |
-27.82% | 2.32B | |
+25.13% | 2.17B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO